ANIP - Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal | Benzinga
On Monday, ANI Pharmaceuticals Inc (NASDAQ:ANIP) agreed to acquire Alimera Sciences Inc (NASDAQ:ALIM) for $5.50 per share in cash and one non-tradable contingent value right (CVR) of up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
ANI will also repay $72.5 million of Alimera debt.
The transaction, which values Alimera at approximately $381 million in upfront consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024.
Alimera’s two commercial products include
- Iluvien (fluocinolone acetonide intravitreal implant 0.19mg) is indicated for diabetic macular edema in the U.S., Europe and the Middle East ...